Adenosine triphosphate-sensitive potassium channel blocking agent ameliorates, but the opening agent aggravates, ischemia/reperfusion-induced injury. Heart function studies in nonfibrillating isolated hearts

School of Medicine, University of Connecticut Health Center, Farmington 06030-1110.

OBJECTIVES. This study was conducted to elucidate the role of the adenosine triphosphate (ATP)-sensitive potassium channel blocking agent glibenclamide and the opener cromakalim in the mechanism of reperfusion-induced injury. BACKGROUND. Recently, ATP-sensitive potassium channel openers have been proposed to reduce ischemia/reperfusion-induced injury, including arrhythmias and heart function. Thus, one might hypothesize that pharmacologic agents that enhance the loss of potassium ions in the myocardium through ATP-sensitive potassium channels would be arrhythmogenic, and agents that interfere with tissue potassium ion loss would be antiarrhythmic. METHODS. Isolated "working" guinea pig hearts and phosphorus-31 nuclear magnetic resonance spectroscopy were used to study the recovery of myocardial function and phosphorus compounds after 30, 40 and 50 min of normothermic global ischemia followed by reperfusion in untreated control and glibenclamide- and cromakalim-treated groups. RESULTS. After 30 min of ischemia, 1, 3, 10 and 30 mumol/liter of glibenclamide dose-dependently reduced the incidence of reperfusion-induced ventricular fibrillation (total) from its control value of 92% to 75%, 33% (p < 0.05), 33% (p < 0.05) and 42% (p < 0.05), respectively. The incidence of ventricular tachycardia followed the same pattern. A reduction of arrhythmias was also observed after 40 and 50 min of ischemia followed by reperfusion in the glibenclamide-treated hearts. Cromakalim, at the same concentrations, did not reduce the incidence of reperfusion-induced arrhythmias. During reperfusion, glibenclamide (3 and 10 mumol/liter) improved the recovery of coronary blood flow, aortic flow, myocardial contractility and tissue ATP and creatine phosphate content, but cromakalim failed to ameliorate the recovery of postischemic myocardium compared with that in the drug-free control hearts. CONCLUSIONS. The preservation of myocardial potassium ions and phosphorus compounds by glibenclamide can improve the recovery of postischemic function, but the use of ATP-sensitive potassium channel openers as antihypertensive or antiarrhythmic agents may be of particular concern in those postinfarction patients who are known to be at high risk for sudden cardiac death.

This article has been cited by other articles:

				T. Pataki, I. Bak, P. Kovacs, D. Bagchi, D. K Das, and A. Tosaki Grape seed proanthocyanidins improved cardiac recovery during reperfusion after ischemia in isolated rat hearts Am. J. Clinical Nutrition, May 1, 2002; 75(5): 894 - 899. [Abstract] [Full Text] [PDF]

				K. N. Jew and R. L. Moore Glibenclamide improves postischemic recovery of myocardial contractile function in trained and sedentary rats J Appl Physiol, October 1, 2001; 91(4): 1545 - 1554. [Abstract] [Full Text] [PDF]

				H. Gögelein, J. Hartung, H. C. Englert, and B. A. Schölkens HMR 1883, a Novel Cardioselective Inhibitor of the ATP-Sensitive Potassium Channel. Part I: Effects on Cardiomyocytes, Coronary Flow and Pancreatic beta -Cells J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1453 - 1464. [Abstract] [Full Text]

				G. E. Billman, H. C. Englert, and B. A. Schölkens HMR 1883, a Novel Cardioselective Inhibitor of the ATP-Sensitive Potassium Channel. Part II: Effects on Susceptibility to Ventricular Fibrillation Induced by Myocardial Ischemia in Conscious Dogs J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1465 - 1473. [Abstract] [Full Text]

				A. Tosaki, N. Maulik, G. T. Elliott, I. E. Blasig, R. M. Engelman, and D. K. Das Preconditioning of Rat Heart with Monophosphoryl Lipid A: A Role for Nitric Oxide J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1274 - 1279. [Abstract] [Full Text] [PDF]

				A. Tosaki and D. K. Das Extracellular Mg++ Manipulation Prevents the Proarrhythmic Activity of Cromakalim in Ischemic/Reperfused Diabetic Hearts J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 309 - 317. [Abstract] [Full Text]

				R. L. Engler and D. M. Yellon Sulfonylurea KATP Blockade in Type II Diabetes and Preconditioning in Cardiovascular Disease: Time for Reconsideration Circulation, November 1, 1996; 94(9): 2297 - 2301. [Full Text]

				K. N. Jew and R. L. Moore Exercise training alters an anoxia-induced, glibenclamide-sensitive current in rat ventricular cardiocytes J Appl Physiol, April 1, 2002; 92(4): 1473 - 1479. [Abstract] [Full Text] [PDF]